US5697902A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for imaging and treating organs and tissues
Assignee: Immunomedics Inc
•
Filing: 1995-06-01
•
Granted: 1997-12-16
•
Expires: 2015-06-01
Abstract
Abstract Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.
Inventors
- 👤 Milton David Goldenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:34
CPC Classifications
G; G01; G01R; G01R33/00; G01R33/20; G01R33/44; G01R33/48; G01R33/54; G01R33/56; G01R33/5601; A; A61; A61K; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K51/1027; A61K51/1036; A61K51/1039; A61K51/1045; A61K51/1057; A61K51/1072; A61P; A61P35/00; A61P37/00; A61P37/02; A61P37/06; A61P43/00; B; B82; B82Y; B82Y5/00; A61K2123/00; Y; Y10; Y10S; Y10S424/00; Y10S424/81; Y10S530/00; Y10S530/868
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
69 words
Method for ablating non-malignant cells or tissue in a patient, the method comprising treating the patient with an antibody or antibody fragment specific to a marker associated with or produced by the cells or tissue to be ablated and which is conjugated to a cytotoxic agent, wherein said non-malignant cells or tissue are selected from the group consisting of ectopic tissue, retained tissue, normal organ tissue and bone marrow.
Claim 2
Dependent Claim
69 words
Method for ablating non-malignant cells or tissue in a patient, the method comprising treating the patient with an antibody or antibody fragment specific to a marker associated with or produced by the cells or tissue to be ablated and which is conjugated to a cytotoxic agent, wherein said non-malignant cells or tissue are selected from the group consisting of ectopic tissue, retained tissue, normal organ tissue and bone marrow.
Claim 3
Dependent Claim
24 words
The method of claim 1 wherein the cytotoxic agent is an isotope, drug, toxin, fluorescent dye activated by nonionizing radiation, hormone, autocrine or cytokines.
Claim 4
Dependent Claim
36 words
The method of claim 2 wherein the isotope is selected from the group consisting of Iodine-125, Iodine-131, Rhenium-186, Rhenium-188, Silver-111, Platinum-197, Palladium-109, Copper-67, Phosphorus-32, Phosphorus-33, Yttrium-90, Scandium-47, Samarium-153, Lutetium-177, Rhodium-105, Praseodymium-142, Praseodymium-143, Terbium-161, Holmium-166 and Gold-199.
Claim 5
Dependent Claim
62 words
The method of claim 2 wherein the cytotoxic agent is selected from the group consisting of taxol, mechlorethamine, cyclophosphamide, melphalan, uracil mustard, chlorambucil, thiotepa, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, methotrexate, fluorouracil, cytarabine, azaribine, mercaptopurine, thioguanine, vinblastine, vincristine, dactinomycin, daunorubicin, doxorubicin, bleomycin, mithramycin, mitomycin, L-asparaginase, cisplatin, hydroxyurea, procarbazine, mitotane, prednisone, hydroxyprogesterone caproate, medroprogesterone acetate, diethylstilbestrol, ethinyl estradiol, tamoxifen, testosterone propionate and fluoxymesterone.
Claim 6
Dependent Claim
56 words
The method of claim 2, wherein the cell or tissue is pretargeted by injecting the subject with a first composition which comprises biotinylated antibody or fragment, optionally injecting the subject with a clearing composition comprising an agent to clear circulating biotinylated antibody or fragment, and then injecting a second composition which comprises biotin conjugated with isotope.
Claim 7
Dependent Claim
23 words
The method of claim 1 wherein the antibody is an Fv, single chain antibody, Fab, Fab', or F(ab') 2 fragment or intact antibody.
Claim 8
Dependent Claim
33 words
The method of claim 1 wherein the antibody or fragment has a specific immunoreactivity to targeted cells or tissues of at least 60% and a cross-reactivity to other antigens of less than 35%.
Claim 9
Dependent Claim
99 words
The method of claim 1 wherein the cell or tissue is pretargeted with a first composition comprising a streptavidin-conjugated antibody, biotinylated antibody used in conjunction with avidin and biotin, bifunctional antibody, antibody-hapten complex, or enzyme-conjugated antibody, wherein the antibody is an antibody or antibody fragment which specifically binds a marker produced by or associated with said cell or tissue, and after the first composition accretes at the targeted tissue or cell, a second composition is administered which activates a therapeutic agent on the first composition or couples a therapeutic agent to the first composition to produce a therapeutic agent.
Claim 10
Dependent Claim
14 words
The method of claim 1, wherein said non-malignant cells or tissue are ectopic tissue.
Claim 11
Dependent Claim
12 words
The method of claim 9, wherein said ectopic tissue is endometrial tissue.
Claim 12
Dependent Claim
14 words
The method of claim 1, wherein said non-malignant cells or tissue are retained tissue.
Claim 13
Dependent Claim
15 words
The method of claim 1, wherein said non-malignant cells or tissue are normal organ tissue.
Claim 14
Dependent Claim
13 words
The method of claim 12, wherein said normal organ tissue is spleen tissue.
Claim 15
Dependent Claim
14 words
The method of claim 1, wherein said non-malignant cells or tissue are bone marrow.
References Cited (Backward Citations)
US3927193A
Cited
US4036945A
Cited
US4331647A
Cited
US4348376A
Cited
US4361544A
Cited
US4444744A
Cited
US4440747A
Cited
US4489710A
Cited
US4732864A
Cited
US4735210A
Cited
US5510105A
Cited
US4859449A
Cited
US5208021A
Cited
EP0330201A2
Cited
US5011689A
Cited
US5326559A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-12-15 | 2001-06-16 | 2001-12-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-12-15 | 2005-06-16 | 2005-12-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-12-15 | 2009-06-16 | 2009-12-16 | $7700.00 | Window Closed / Lapsed |